Role of autoimmunity in heart disease: Is chagas heart disease the definitive proof?

Canadian Journal of Cardiology

Volumn 30, Issue 3, 2014, Pages 267-269

  McLean, Brent A ^a   Oudit, Gavin Y ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ANIMALS; ANTIBODIES, PROTOZOAN; CHAGAS CARDIOMYOPATHY; FEMALE; HUMANS; MALE; TRYPANOSOMA CRUZI;

EID: 84894268650     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.10.006     Document Type: Editorial

References (16)

1. Schmunis G.A. Epidemiology of Chagas disease in non-endemic countries: the role of international migration. Mem Inst Oswaldo Cruz 2007, 102(suppl 1):75-85.
2. Rassi A., Rassi A., Marin-Neto J.A. Chagas disease. Lancet 2010, 375:1388-1402.
3. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013, 62:e147-e239.
4. Marin-Neto J.A., Cunha-Neto E., Maciel B.C., Simoes M.V. Pathogenesis of chronic Chagas heart disease. Circulation 2007, 115:1109-1123.
5. Ribeiro A.L., Nunes M.P., Teixeira M.M., Rocha M.O. Diagnosis and management of Chagas disease and cardiomyopathy. Nat Rev Cardiol 2012, 9:576-589.
6. Gea S., Ordonez P., Cerban F., et al. Chagas' disease cardioneuropathy: association of anti-Trypanosoma cruzi and anti-sciatic nerve antibodies. Am J Med Trop Hyg 1993, 49:581-588.
7. Eriksson U., Ricci R., Hunziker L., et al. Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat Med 2003, 9:1484-1490.
8. Pontes-de-Carvalho L., Santana C.C., Soares M.B., et al. Experimental chronic Chagas' disease myocarditis is an autoimmune disease preventable by induction of immunological tolerance to myocardial antigens. J Autoimmun 2002, 18:131-138.
9. Cremaschi G., Fernandez M.M., Gorelik G., et al. Modulatory effects on myocardial physiology induced by an anti-Trypanosoma cruzi monoclonal antibody involve recognition of major antigenic epitopes from beta1-adrenergic and M2-muscarinic cholinergic receptors without requiring receptor cross-linking. J Neuroimmunol 2004, 153:99-107.
10. Patel P.A., Hernandez A.F. Targeting anti-beta-1-adrenergic receptor antibodies for dilated cardiomyopathy. Eur J Heart Fail 2013, 15:724-729.
11. von Kreuter B.F., Santos-Buch C.A. Modulation of Trypanosoma cruzi adhesion to host muscle cell membranes by ligands of muscarinic cholinergic and beta adrenergic receptors. Mol Biochem Parasitol 1989, 36:41-50.
12. Borda E.S., Sterin-Borda L.J., Pascual J.O., et al. Trypanosoma cruzi attachment to lymphocyte muscarinic cholinergic and beta adrenergic receptors modulates intracellular signal transduction. Mol Biochem Parasitol 1991, 47:91-100.
13. Elies R., Ferrari I., Wallukat G., et al. Structural and functional analysis of the B cell epitopes recognized by anti-receptor autoantibodies in patients with Chagas' disease. J Immunol 1996, 157:4203-4211.
14. Lopez Bergami P., Scaglione J., Levin M.J. Antibodies against the carboxyl-terminal end of the Trypanosoma cruzi ribosomal p proteins are pathogenic. FASEB J 2001, 15:2602-2612.
15. Vicco M.H., Pujato N., Bontempi I., et al. β1-selective adrenoceptor antagonists increase plasma levels of anti-p2β antibodies and decrease cardiac involvement in chronic progressive Chagas heart disease. Can J Cardiol 2014, 30:332-337.
16. Nascimento C.A., Gomes V.A., Silva S.K., et al. Left atrial and left ventricular diastolic function in chronic Chagas disease. J Am Soc Echocardiogr 2013, 26:1424-1433.